T-cell gene therapy.
In the past year, a number of human gene therapy trials involving the adoptive transfer of genetically modified T lymphocytes have been reported. These include trials of adenosine deaminase gene transfer in children with severe combined immunodeficiency syndrome, a gene-marking study of Epstein-Barr virus-specific cytotoxic T cells, and trials of gene-modified T cells expressing suicide or viral resistance genes in patients infected with HIV. Additional strategies for T-cell gene therapy currently being pursued in the clinic involve the engineering of novel T-cell receptors that impart antigen specificity for virally infected or malignant cells.
Hege
K M
KM
Cell Genesys Inc, 322 Lakeside Drive, Foster City, CA 94404, USA. hege_kristen@cellgenesys.com
Roberts
M R
MR
D000243:Adenosine Deaminase / Q000172:deficiency / Q000235:genetics; D015496:CD4-Positive T-Lymphocytes; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods*; D015658:HIV Infections / Q000235:genetics / Q000517:prevention & control; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy; D016511:Severe Combined Immunodeficiency / Q000235:genetics / Q000628:therapy; D013601:T-Lymphocytes; D013602:T-Lymphocytes, Cytotoxic; D014777:Virus Diseases / Q000235:genetics / Q000628:therapy
D000243:Adenosine Deaminase